

## **BelHealth Investment Partners and Precision Toxicology Announce Board of Directors**

*Seasoned group of executives added to assist the Company in the next phase of national expansion*

New York, NY – May 22, 2014 – BelHealth Investment Partners (“BelHealth”), a healthcare-focused private equity firm, and Precision Toxicology (“Precision” or the “Company”), a BelHealth portfolio company and leading provider of toxicology services, are pleased to announce the Company’s Board of Directors. The Board includes: Dr. Arthur B. Laffer, Mark Bortnick, Jason Hansen, David Sturek, Dennis Drislane and Harold S. Blue.

Dr. Laffer is a world renowned economist who founded and is Chairman of Laffer Associates, an economic research and consulting firm that provides global investment-research services to institutional asset managers, pension funds, financial institutions and corporations. Mr. Bortnick is the co-founder and Chief Operating Officer (“COO”) of Linden Care, a BelHealth portfolio company. Mr. Hansen, founder and CEO of Precision, is a successful entrepreneur with a background in Science and Engineering. The remaining Board members are Harold S. Blue and Dennis Drislane, BelHealth Managing Partners and David Sturek, BelHealth Managing Director.

Dr. Laffer, BelHealth Advisory Board Member said, “I have enjoyed my partnership with BelHealth immensely and look forward to joining my second portfolio company Board. Lower middle market healthcare services companies play a critical role in the healthcare economy. The toxicology space in particular is poised to have an outsized influence as the need to manage and maintain compliance amongst patients taking pain medications has never been greater. I am excited to partner with the young and energetic management team at Precision and build a national leader in toxicology.”

Harold S. Blue said, "Our Board, led by BelHealth, will drive substantial synergies amongst the BelHealth portfolio and Precision. We are off to a quick start having already added two key executives to complement the existing management team. We are excited about partnering with Precision’s terrific management team and providing support in the form of corporate governance, strategic growth initiatives and synergies amongst the BelHealth portfolio to drive substantial future growth.”

### **About Precision Toxicology**

Precision, headquartered in San Diego, California, is a clinical laboratory that specializes in providing quantitative drug testing, primarily for the purpose of helping physicians monitor their patients undergoing treatment for pain or substance abuse. Precision’s objective is to improve patient adherence/compliance with their prescription regimen and protect medical practices from liability. The Company has experienced rapid growth since inception and will continue to expand its successful strategy throughout the rest of the country, becoming a leading, national clinical toxicology lab.

**About BelHealth Investment Partners**

BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth acquires majority positions in entrepreneur-owned companies we believe would benefit from our vast operating and private equity experience. The firm typically invests \$10-25 million per platform company across four healthcare segments: Services, Products, Distribution and Information Technology. Applying an active, hands-on approach, BelHealth utilizes its experience to support management to drive revenue, profit growth and achieve superior returns for our investors and partners.

**For further information, please visit:**

Precision Toxicology: [www.precisiontoxicology.com](http://www.precisiontoxicology.com)

BelHealth Investment Partners: [www.belhealth.com](http://www.belhealth.com)

**Contact:**

Precision Toxicology: Jason Hansen (800) 635-6901

BelHealth Investment Partners: David Sturek (347) 308-7019